Virtual Library
Start Your Search
M. Carbonnaux
Author of
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-039 - A World of EGFR Screening Test (ID 2406)
09:30 - 09:30 | Author(s): M. Carbonnaux
- Abstract
Background:
EGFR mutation status has emerged as a crucial issue in the management of lung cancer. In France, the national cancer institute has launched a network of EGFR screening test facilities for daily practice. There is however very little information about EGFR screening test and TKI drugs availability in routine at a worldwide level. We also hypothesized that inequalities might occur in the EGFR test availability regarding country development. Thus, the aim of this study was to edit a map of routine EGFR test and drugs availability and cost subsequently associated to development indicators.
Methods:
We conducted a prospective expert opinion survey. An electronic questionnaire, edited in French or English, was addressed to experts in thoracic oncology in each country of the world. Experts were selected by three different ways: (i) email lists of partner institutions (the European Respiratory Society, the Asian Pacific Society of Respiratory, the Asociacion Latinoamericana del Torax, the Thoracic society of Australia and New Zealand), (ii) manual research on the internet, and (iii) the IASLC member. Interpretation of multiple answers was performed according to an a priori determined algorithm. Questionnaire contained 10 multiple-choice questions on availability, and cost of EGFR screening test and EGFR tyrosine kinases inhibitors (TKI). Country development was estimated by the human development index (HDI) provided by UN development program.
Results:
We obtained answer from 74 countries, covering 78% of world population according to UN data. Experts (n=100) were mainly clinicians and worked in hospitals or cancer centers. Non-responding countries were mainly from Africa and Asia, and had a significantly lower HDI than responding countries. EGFR screening test was routinely available in whole the country or only in some region for 57 countries (70% of the world population; figure 1). The remaining-cost of the test was less than 500 US$ in 49 countries (42.5% of the population). Availability and cost of the test were both significantly linked to HDI. The delay to obtain test result was less than 30 working-days in 71% of the population. Erlotinib, Gefitinib, Afatinib and Icotinib were routinely available in 75%, 66%, 31% and 23% of the world population respectively. Availability and cost of erlotinib, gefitinib and afatinib were also associated to HDI. Figure 1
Conclusion:
EGFR screening test and EGFR TKI are widely accessible in routine worldwide. However, there are large discrepancies in the access and the cost of this innovative process regarding development index.
